|
1
|
Barta JA, Powell CA and Wisnivesky JP:
Global epidemiology of lung cancer. Ann Glob Health. 85:82019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thandra KC and Barsouk A, Saginala K,
Aluru JS and Barsouk A: Epidemiology of lung cancer. Contemp Oncol
(Pozn). 25:45–52. 2021.PubMed/NCBI
|
|
3
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
GBD 2021 Diseases and Injuries
Collaborators, . Global incidence, prevalence, years lived with
disability (YLDs), disability-adjusted life-years (DALYs), and
healthy life expectancy (HALE) for 371 diseases and injuries in 204
countries and territories and 811 subnational locations, 1990–2021:
A systematic analysis for the Global Burden of Disease Study 2021.
Lancet. 403:2133–2161. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garinet S, Wang P, Mansuet-Lupo A, Fournel
L, Wislez M and Blons H: Updated prognostic factors in localized
NSCLC. Cancers (Basel). 14:14002022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Puderecki M, Szumiło J and Marzec-Kotarska
B: Novel prognostic molecular markers in lung cancer. Oncol Lett.
20:9–18. 2020.PubMed/NCBI
|
|
8
|
Mahar AL, Compton C, McShane LM, Halabi S,
Asamura H, Rami-Porta R and Groome PA; Molecular Modellers Working
Group of American Joint Committee on Cancer, : Refining prognosis
in lung cancer: A report on the quality and relevance of clinical
prognostic tools. J Thorac Oncol. 10:1576–1589. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dimopoulos MA and Terpos E: Renal
insufficiency and failure. Hematology Am Soc Hematol Educ Program.
2010:431–436. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kovesdy CP: Epidemiology of chronic kidney
disease: An update 2022. Kidney Int Suppl (2011). 12:7–11. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stengel B: Chronic kidney disease and
cancer: A troubling connection. J Nephrol. 23:253–262.
2010.PubMed/NCBI
|
|
12
|
Malyszko J, Tesarova P, Capasso G and
Capasso A: The link between kidney disease and cancer:
Complications and treatment. Lancet. 396:277–287. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu M, Wang Q, Liu B, Ma Q, Zhang T, Huang
T, Lv Z and Wang R: Chronic Kidney disease and cancer:
Inter-relationships and mechanisms. Front Cell Dev Biol.
10:8687152022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shlipak MG, Katz R, Kestenbaum B, Fried
LF, Newman AB, Siscovick DS, Stevens L and Sarnak MJ: Rate of
kidney function decline in older adults: A comparison using
creatinine and cystatin C. Am J Nephrol. 30:171–178. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lees JS, Elyan BMP, Herrmann SM, Lang NN,
Jones RJ and Mark PB: The ‘other’ big complication: How chronic
kidney disease impacts on cancer risks and outcomes. Nephrol Dial
Transplant. 38:1071–1079. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu MS, Chen MF, Yang YH, Lee CP, Lin CC,
Tseng YH and Tsai YH: Appraisal of lung cancer survival in patients
with end-stage renal disease. Arch Med Sci. 19:86–93.
2023.PubMed/NCBI
|
|
17
|
Saito T, Murakawa T, Shintani Y, Okami J,
Miyaoka E, Yoshino I and Date H; Japanese Joint Committee of Lung
Cancer Registry, : Preoperative renal dysfunction and long-term
survival after surgery for non-small cell lung cancer. J Thorac
Cardiovasc Surg. 164:227–239.e6. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei YF, Chen JY, Lee HS, Wu JT, Hsu CK and
Hsu YC: Association of chronic kidney disease with mortality risk
in patients with lung cancer: A nationwide Taiwan population-based
cohort study. BMJ Open. 8:e0196612018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: PRISMA. Transparent reporting of systematic reviews and
meta-analyses. BMJ. 372:n712021. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wells G, Shea B, O'Connell D, Robertson J,
Peterson J, Losos M and Tugwell P: The Newcastle-Ottawa Scale (NOS)
for Assessing the Quality of Nonrandomized Studies in
Meta-analysis. Jan;2024.
|
|
21
|
Egger M, Davey Smith G, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cho S, Kang E, Kim JE, Kang U, Kang HG,
Park M, Kim K, Kim DK, Joo KW, Kim YS, et al: Clinical significance
of acute kidney injury in lung cancer patients. Cancer Res Treat.
53:1015–1023. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia W, Wang C and Cheng Y: Decreased
preoperative estimated glomerular filtration rate was related with
poor prognosis of NSCLC patients. Technol Cancer Res Treat.
19:15330338209523552020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Magali L, Pascal F, Serge A, Mathieu B,
Ayoube Z, Claire T and Christiane M: Better survival in impaired
renal function patients with metastatic non-small cell lung cancer
treated by cisplatin-pemetrexed. Eur J Clin Pharmacol.
76:1573–1580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamamoto Y, Kanzaki R, Kanou T, Ose N,
Funaki S, Minami M and Shintani Y: Long-term outcomes of pulmonary
resection for lung cancer patients with chronic kidney disease.
World J Surg. 43:3249–3258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Y, Li H-Y, Zhou Q, Peng ZW, An X, Li
W, Xiong LP, Yu XQ, Jiang WQ and Mao HP: Renal function and
all-cause mortality risk among cancer patients. Medicine
(Baltimore). 95:e37282016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kutluk Cenik B, Sun H and Gerber DE:
Impact of renal function on treatment options and outcomes in
advanced non-small cell lung cancer. Lung Cancer. 80:326–332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tammemagi CM, Neslund-Dudas C, Simoff M
and Kvale P: Impact of comorbidity on lung cancer survival. Int J
Cancer. 103:792–802. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
ICD-9-CM official guidelines for coding
and reporting. Aug 23–2011.
|
|
30
|
Levey AS, Stevens LA, Schmid CH, Zhang YL,
Castro AF III, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene
T, et al: A new equation to estimate glomerular filtration rate.
Ann Intern Med. 150:604–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Earley A, Miskulin D, Lamb EJ, Levey AS
and Uhlig K: Estimating equations for glomerular filtration rate in
the era of creatinine standardization: A systematic review. Ann
Intern Med. 156:785–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Michels WM, Grootendorst DC, Verduijn M,
Elliott EG, Dekker FW and Krediet RT: Performance of the
Cockcroft-gault, MDRD, and new CKD-EPI formulas in relation to GFR,
age, and body size. Clin J Am Soc Nephrol. 5:1003–1009. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stevens LA, Schmid CH, Greene T, Zhang YL,
Beck GJ, Froissart M, Hamm LL, Lewis JB, Mauer M, Navis GJ, et al:
Comparative performance of the CKD Epidemiology Collaboration
(CKD-EPI) and the modification of diet in renal disease (MDRD)
study equations for estimating GFR levels above 60 mL/min/1.73 m2.
Am J Kidney Dis. 56:486–495. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Launay-Vacher V, Oudard S, Janus N,
Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P and Deray G;
Renal Insufficiency and Cancer Medications (IRMA) Study Group, :
Prevalence of Renal Insufficiency in cancer patients and
implications for anticancer drug management: The renal
insufficiency and anticancer medications (IRMA) study. Cancer.
110:1376–1384. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kato S, Chmielewski M, Honda H,
Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P and
Lindholm B: Aspects of immune dysfunction in end-stage renal
disease. Clin J Am Soc Nephrol. 3:1526–1533. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Launay-Vacher V, Janus N and Deray G:
Renal insufficiency and cancer treatments. ESMO Open.
1:e0000912016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Swamy S, Noor SM and Mathew RO:
Cardiovascular disease in diabetes and chronic kidney disease. J
Clin Med. 12:69842023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim S, Kim G and Kim JH: Additive
interaction of diabetes mellitus and chronic kidney disease in
cancer patient mortality risk. Sci Rep. 12:199572022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Khorana AA, Tullio K, Elson P, Pennell NA,
Grobmyer SR, Kalady MF, Raymond D, Abraham J, Klein EA, Walsh RM,
et al: Time to initial cancer treatment in the United States and
association with survival over time: An observational study. PLoS
One. 14:e02132092019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cone EB, Marchese M, Paciotti M, Nguyen
DD, Nabi J, Cole AP, Molina G, Molina RL, Minami CA, Mucci LA, et
al: Assessment of Time-to-Treatment initiation and survival in a
cohort of patients with common cancers. JAMA Netw Open.
3:e20300722020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tinti F, Lai S, Noce A, Rotondi S, Marrone
G, Mazzaferro S, Di Daniele N and Mitterhofer AP: Chronic kidney
disease as a systemic inflammatory syndrome: Update on mechanisms
involved and potential treatment. Life (Basel).
11:4192021.PubMed/NCBI
|
|
42
|
Espi M, Koppe L, Fouque D and Thaunat O:
Chronic kidney disease-associated immune dysfunctions: Impact of
protein-bound uremic retention solutes on immune cells. Toxins
(Basel). 12:3002020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sprangers B, Perazella MA, Lichtman SM,
Rosner MH and Jhaveri KD: Improving cancer care for patients with
CKD: The need for changes in clinical trials. Kidney Int Rep.
7:1939–1950. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shirali AC and Sprangers B: Cancer drug
dosing in chronic kidney disease and dialysis. Adv Chronic Kidney
Dis. 29:208–216.e1. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Verma S, Singh P, Khurana S, Ganguly NK,
Kukreti R, Saso L, Rana DS, Taneja V and Bhargava V: Implications
of oxidative stress in chronic kidney disease: A review on current
concepts and therapies. Kidney Res Clin Pract. 40:183–193. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Oberacker T, Fritz P, Schanz M, Alscher
MD, Ketteler M and Schricker S: Enhanced oxidative DNA-damage in
peritoneal dialysis patients via the TXNIP/TRX axis. Antioxidants
(Basel). 11:11242022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cartwright DJ: ICD-9-CM to ICD-10-CM
codes: What? Why? How? Adv Wound Care (New Rochelle). 2:588–592.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sorino C, Scichilone N, Pedone C, Negri S,
Visca D and Spanevello A: When kidneys and lungs suffer together. J
Nephrol. 32:699–707. 2019. View Article : Google Scholar : PubMed/NCBI
|
